Carvedilol could be the poster child for how to lower drug prices. Since 2007, over 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which ...

November 17, 2006 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise on the use of carvedilol tablets in diabetic patients; the risk for potentially fatal ...

Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 million judgment against generics maker Teva. In the patent "carve-out" case, GSK didn't bring enough ...

The U.S. Food and Drug Administration today approved the first generic versions of Coreg (carvedilol). Coreg is a widely used medication that is FDA-approved to treat high blood pressure, mild to ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The US District Court for the District of Delaware granted in part Teva Pharmaceuticals’ renewed motion for judgment as a matter of law (JMOL), finding that substantial evidence did not support the ...

(Reuters) - A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents ...

As of May 2026, the pharmacy landscape is defined by a paradox: Carvedilol is absent from official shortage lists, yet patients are reporting significant access issues due to fragmented generic supply ...

The use of low-dose carvedilol did not significantly improve certain cardiac measures of heart failure risk in long-term survivors of childhood cancer exposed to anthracycline compared with placebo, ...

Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, ...